Skip to main content

Grafa News and Videos — Page 1107

Grafa Headlines

Latest

Grafa

Alvotech resubmits FDA applications for Simponi and Eylea biosimilars

Alvotech (NASDAQ:ALVO) has officially resubmitted its Biologics License Applications (BLAs) to the U.S. Food and Drug Administration (FDA) for two of its lead biosimilar candidates: AVT05, a proposed biosimilar to Simponi and Simponi Aria (golimumab), and AVT06, a proposed biosimilar to Eylea (aflibercept) 2 mg.

Read more: Alvotech resubmits FDA applications for Simponi and Eylea biosimilars
Grafa

Biogen and UCB present positive Phase 3 PHOENYCS GO data for lupus candidate dapirolizumab pegol

Biogen (NASDAQ:BIIB) and UCB have announced the release of positive results from the Phase 3 PHOENYCS GO clinical trial evaluating dapirolizumab pegol (DZP), an investigational treatment for systemic lupus erythematosus (SLE).

Read more: Biogen and UCB present positive Phase 3 PHOENYCS GO data for lupus candidate dapirolizumab pegol

GET YOUR GRAFA EDGE NOW

We'll switch on a 30-day Edge trial as a welcome gift